SPOTLIGHT -
Quantitative analysis of the impact of neovascular age-related macular degeneration (AMD) on the UK population has led a team of researchers to call for urgent, early access to the new class of drug therapies for the disease.
Outlook Therapeutics submits UK Marketing Authorisation Application for wet AMD treatment
The submission for bevacizumab gamma (ONS-5010/LYTENAVA) follows a positive opinion from the CHMP in March
Going beyond the clinical setting in ophthalmic mentorship
Three leaders in glaucoma research, retina care and refractive surgery share their expertise
ARVO 2024: Non-invasive testing could use tear film to screen for changes in Huntington Disease
The mutant huntingtin protein in tear fluid may have the potential to serve as an early marker of changes in Huntington disease
ARVO 2024: Diabetic retinopathy risk factors in paediatric patients with Type 1 diabetes
Study results indicate that maintaining control of blood pressure and hemoglobin A1c are key to preventing the onset of diabetic retinopathy
ARVO 2024: Murine model of multiple sclerosis demonstrates correlation between visual markers and motor-sensory deficits
Study data demonstrated a significant correlation between visual function, structure and neurological impairment in an experimental autoimmune encephalomyelitis model
May is Inherited Retinal Disease Genetic Testing Awareness Month, Prevent Blindness expands on previous weeklong campaign
During the month of May, Prevent Blindness will offer fact sheets, videos and other resources for IRD education